X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1423) 1423
Book Review (423) 423
Publication (78) 78
Magazine Article (50) 50
Newspaper Article (44) 44
Government Document (20) 20
Book Chapter (18) 18
Trade Publication Article (18) 18
Conference Proceeding (12) 12
Book / eBook (5) 5
Newsletter (4) 4
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (970) 970
humans (936) 936
biosimilar (404) 404
pharmacology & pharmacy (398) 398
biosimilar pharmaceuticals - therapeutic use (395) 395
biosimilars (392) 392
biological products (389) 389
biosimilar pharmaceuticals (383) 383
safety (247) 247
united states (238) 238
oncology (229) 229
pharmaceutical industry (217) 217
female (216) 216
drug approval (214) 214
male (208) 208
biosimilar pharmaceuticals - adverse effects (200) 200
biosimilar pharmaceuticals - administration & dosage (181) 181
adult (175) 175
animals (171) 171
immunogenicity (168) 168
infliximab (157) 157
middle aged (155) 155
therapeutic equivalency (154) 154
double-blind (150) 150
drugs (150) 150
efficacy (150) 150
treatment outcome (144) 144
analysis (143) 143
antibodies (134) 134
biosimilar pharmaceuticals - economics (132) 132
rheumatology (132) 132
fda approval (130) 130
united states food and drug administration (130) 130
monoclonal antibodies (129) 129
generic drugs (123) 123
medicine & public health (121) 121
biosimilar pharmaceuticals - pharmacokinetics (118) 118
clinical trials (118) 118
medicine, research & experimental (115) 115
pharmacokinetics (114) 114
pharmacology (114) 114
research (114) 114
biotechnology (112) 112
biotechnology & applied microbiology (111) 111
cancer (111) 111
europe (106) 106
biosimilar pharmaceuticals - pharmacology (102) 102
immunology (102) 102
patients (102) 102
laws, regulations and rules (101) 101
proteins (101) 101
rheumatoid arthritis (100) 100
studies (96) 96
aged (94) 94
biosimilar pharmaceuticals - standards (94) 94
innovator infliximab (93) 93
care and treatment (91) 91
chemotherapy (90) 90
usage (90) 90
antibodies, monoclonal - therapeutic use (89) 89
parallel-group (88) 88
arthritis (83) 83
biologics (83) 83
manufacturing (82) 82
review (82) 82
biopharmaceuticals (81) 81
drug therapy (81) 81
biosimilar pharmaceuticals - chemistry (80) 80
ct-p13 (80) 80
biomedicine (79) 79
medicine (79) 79
hematology (75) 75
rheumatoid-arthritis (75) 75
young adult (75) 75
pharmacovigilance (74) 74
biological products - therapeutic use (73) 73
filgrastim (73) 73
comparability (71) 71
dosage and administration (71) 71
drug approval - legislation & jurisprudence (70) 70
product development (70) 70
cancer research (69) 69
medical research (69) 69
patents (69) 69
internal medicine (68) 68
health aspects (67) 67
interchangeability (67) 67
pharmacotherapy (67) 67
arthritis, rheumatoid - drug therapy (65) 65
colony-stimulating factor (64) 64
double-blind method (64) 64
therapy (64) 64
antirheumatic agents - therapeutic use (62) 62
medicine, general & internal (61) 61
neoplasms - drug therapy (61) 61
pharmacology/toxicology (61) 61
pharmaceuticals (60) 60
psoriasis (60) 60
granulocyte colony-stimulating factor (59) 59
adalimumab (57) 57
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1528) 1528
German (13) 13
French (8) 8
Spanish (6) 6
Polish (4) 4
Russian (4) 4
Italian (2) 2
Czech (1) 1
Hungarian (1) 1
Korean (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Digestive Diseases and Sciences, ISSN 0163-2116, 11/2017, Volume 62, Issue 11, pp. 3117 - 3122
Limited data are available on long-term clinical outcomes regarding the switch from Remicade® to the infliximab biosimilar CT-P13 in inflammatory bowel disease... 
Biochemistry, general | Inflammatory bowel diseases | Disease activity | Medicine & Public Health | Infliximab | Switch | Immunogenicity | Hepatology | Gastroenterology | Biosimilar pharmaceuticals | Oncology | Transplant Surgery | ANTIBODIES | TRIAL | SINGLE-CENTER COHORT | CROHNS-DISEASE | GASTROENTEROLOGY & HEPATOLOGY | ORIGINATOR | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gastrointestinal Agents - administration & dosage | Male | Colitis, Ulcerative - immunology | Infliximab - administration & dosage | Feasibility Studies | Young Adult | Infliximab - adverse effects | Netherlands | Crohn Disease - diagnosis | Tumor Necrosis Factor-alpha - immunology | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Female | Colitis, Ulcerative - drug therapy | Gastrointestinal Agents - pharmacokinetics | Biosimilar Pharmaceuticals - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Crohn Disease - immunology | Biosimilar Pharmaceuticals - adverse effects | Colitis, Ulcerative - diagnosis | Antibodies, Monoclonal - administration & dosage | Crohn Disease - drug therapy | Adolescent | Aged | Gastrointestinal Agents - adverse effects | Drug Substitution | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Therapeutic Equivalency | Index Medicus | Abridged Index Medicus | Original
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 917 - 928
Summary Background CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab... 
Hematology, Oncology and Palliative Medicine | NEOADJUVANT TREATMENT | EPIRUBICIN | ONCOLOGY | CONTROLLED SUPERIORITY TRIAL | OPEN-LABEL | PLUS TRASTUZUMAB | CHEMOTHERAPY | BIOSIMILAR MONOCLONAL-ANTIBODIES | PATHOLOGICAL COMPLETE RESPONSE | ADJUVANT TRASTUZUMAB | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Adenocarcinoma - pathology | Febrile Neutropenia - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Epirubicin - administration & dosage | Breast Neoplasms - chemistry | Fluorouracil - administration & dosage | Mastectomy | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Adenocarcinoma - chemistry | Biosimilar Pharmaceuticals - therapeutic use | Biosimilar Pharmaceuticals - administration & dosage | Double-Blind Method | Trastuzumab - adverse effects | Trastuzumab - administration & dosage | Adenocarcinoma - drug therapy | Breast Neoplasms - drug therapy | Biosimilar Pharmaceuticals - adverse effects | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 - analysis | Neoplasm Staging | Adenocarcinoma - surgery | Antimitotic agents | Medical colleges | Adjuvant treatment | Clinical trials | Breast cancer | Product development | Comparative analysis | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Journal Article
Scandinavian Journal of Gastroenterology, ISSN 0036-5521, 09/2016, Volume 51, Issue 9, pp. 1062 - 1068
Journal Article
Journal Article
Journal of Crohn's and Colitis, ISSN 1873-9946, 2/2016, Volume 10, Issue 2, pp. 133 - 140
Journal Article
Inflammatory Bowel Diseases, ISSN 1078-0998, 02/2017, Volume 23, Issue 2, pp. 233 - 243
Journal Article
Journal Article
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 07/2016, Volume 82, Issue 1, pp. 129 - 138
Journal Article
BioDrugs, ISSN 1173-8804, 4/2015, Volume 29, Issue 2, pp. 123 - 131
Biosimilars provide safety, purity, and potency similar to those of a reference biologic product.An array of protein analytical techniques was used to compare... 
Antibodies | Pharmacotherapy | Cancer Research | Molecular Medicine | Biomedicine | PHARMACOLOGY & PHARMACY | IMMUNOLOGY | COLONY-STIMULATING FACTOR | ONCOLOGY | PRODUCT | Amino Acid Sequence | Biosimilar Pharmaceuticals - administration & dosage | Double-Blind Method | Cell Count | Humans | Middle Aged | Neutrophils - drug effects | Recombinant Proteins - chemistry | Biosimilar Pharmaceuticals - chemistry | Recombinant Proteins - pharmacokinetics | Recombinant Proteins - pharmacology | Biosimilar Pharmaceuticals - pharmacology | Filgrastim | Recombinant Proteins - administration & dosage | Cross-Over Studies | Young Adult | Granulocyte Colony-Stimulating Factor - pharmacology | Granulocyte Colony-Stimulating Factor - pharmacokinetics | Adolescent | Biosimilar Pharmaceuticals - pharmacokinetics | Adult | Protein Conformation | Granulocyte Colony-Stimulating Factor - chemistry | Granulocyte Colony-Stimulating Factor - administration & dosage | Biosimilar pharmaceuticals | Pharmacology | Research | Granulocyte colony-stimulating factor | Comparative analysis | Pharmacokinetics | Biological products | Nuclear magnetic resonance--NMR | Laboratories | Chromatography | Biological activity | Studies | Proteins | Comparability | Clinical medicine | Drug therapy | Pharmaceutical industry | Drug dosages | Methods | Index Medicus | Original
Journal Article